Research programme: neurodegenerative disorder therapies - Mitsubishi Tanabe Pharma/Order made Medical Research/Trans Chromosomics

Drug Profile

Research programme: neurodegenerative disorder therapies - Mitsubishi Tanabe Pharma/Order made Medical Research/Trans Chromosomics

Latest Information Update: 19 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Order-made Medical Research; Trans Chromosomics
  • Developer Mitsubishi Tanabe Pharma Corporation; Order-made Medical Research; Trans Chromosomics
  • Class Antibodies; Neuroprotectants
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Neurodegenerative disorders

Most Recent Events

  • 13 Dec 2017 Mitsubishi Tanabe Pharma, Order made Medical Research and Trans Chromosomics agree to co-develop antibody therapeutic for neurodegenerative disorders
  • 13 Dec 2017 Early research in Neurodegenerative disorders in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top